Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - pregabalin, quantity: 75 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; brilliant blue fcf; purified water; sunset yellow fcf; allura red ac; gelatin; sodium lauryl sulfate - cipla pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. cipla pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - pregabalin, quantity: 75 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; brilliant blue fcf; purified water; sunset yellow fcf; allura red ac; gelatin; sodium lauryl sulfate - cipla pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. cipla pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - pregabalin, quantity: 50 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - cipla pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. cipla pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - pregabalin, quantity: 50 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - cipla pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. cipla pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - pregabalin, quantity: 25 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - cipla pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. cipla pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - pregabalin, quantity: 25 mg - capsule - excipient ingredients: purified talc; maize starch; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - cipla pregabalin (pregabalin) is indicated for the treatment of neuropathic pain in adults. cipla pregabalin (pregabalin) is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - isoprenaline hydrochloride, quantity: 1 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - cipla isoprenaline is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation) (see section 4.3 contraindications). - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see section 4.3 contraindications). - for brochospasm occurring during anaesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cariodgenic shock (see section 4.4 special warnings and precautions for use).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - isoprenaline hydrochloride, quantity: 200 microgram - injection, solution - excipient ingredients: disodium edetate; sodium chloride; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - cipla isoprenaline is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation) (see section 4.3 contraindications). - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see section 4.3 contraindications). - for brochospasm occurring during anaesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cariodgenic shock (see section 4.4 special warnings and precautions for use).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - cipla ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - cipla ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.